18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Sponsored by Allergan
About this trial
Last updated 2 years ago
Study ID
MED-MA-EYE-0648
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended a year ago
What is this trial about?
Study to collect effectiveness and safety data after administration of a bimatoprost
intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
What are the participation requirements?
Inclusion Criteria
- Patient diagnosed with OAG or OHT who is scheduled to receive a bimatoprost intracameral implant in at least one eye.
Exclusion Criteria
- A history of any of the following ocular surgeries in the eye due to receive a bimatoprost intracameral implant:Ahmed Glaucoma Valve, Baerveldt shunt, Ex-Press glaucoma shunt implantation, Molteno shunt, Trabeculectomy, Vitrectomy, retinal surgery, CyPass Micro-Stent or Anterior Chamber Intraocular Lens (AC IOL) placement.
- Concurrent or anticipated enrollment in an interventional clinical trial involving either an investigational medicinal product or medical device.
- Previous enrollment in another Allergan bimatoprost intracameral implant study.